Happiness hormones
 

[Solved] Happiness hormones

2 posts
3 users
2 Reactions
1,273 views
0
[#1831]
Topic starter

What do happiness hormones and psychedelics have in common?


2 Answers
1

Happiness hormones, such as serotonin, play a crucial role in our mood and well-being. Psychedelics, such as Psilocybin, work by binding to serotonin receptors in the brain, which leads to increased stimulation of these receptors.

Psychedelics and happiness hormones can often bind to the same receptors because the shape of the molecules is similar. They therefore have virtually the same molecular structure. The same principle applies to many other drugs and medications.


1

The intersection between happiness hormones and psychedelics constitutes a fascinating area of research within neuropharmacology. Recent research shows that both endogenous happiness hormones and exogenous psychedelic substances engage in complex interactions with a broad spectrum of neurotransmitter receptors, with serotonin receptors (particularly 5-HT2A), dopamine receptors (D1 and D2), and NMDA receptors playing a central role. Psychedelics such as psilocybin and LSD exhibit striking parallels with natural neurotransmitters due to their ability to modulate specific receptor populations, resulting in both acute psychoactive effects and long-lasting neuroplastic changes. The degree of receptor stimulation varies significantly between different substances – whereas classic tryptamines such as DMT show a high affinity for 5-HT2A receptors, arylcyclohexylamines such as ketamine prove to be strong NMDA receptor antagonists. These receptor-specific effects offer valuable insights for the development of new therapies for mood disorders.

Neurobiological Basis of Happiness Hormones

Definition and Function of Important Neurotransmitters

Happiness hormones, better known as neurotransmitters and neuropeptides associated with positive affective states, comprise a complex network of serotonin, dopamine, endorphins, oxytocin, GABA, and glutamate. Serotonin (5-hydroxytryptamine) modulates mood, cognition, and perception via seven different receptor families (5-HT1 to 5-HT7). Dopamine, primarily involved in reward processing and motivation, exerts its action via five dopamine receptors (D1-D5). Endorphins, endogenous opioid peptides, interact primarily with μ-opioid receptors (MOR) and are crucial for pain modulation and euphoric experiences.

Physiological Role of Receptor Populations

Each receptor family exhibits unique distribution patterns and signal transduction mechanisms. The 5-HT2A receptor, densely packed in cortical layers V and VI, activates the phospholipase C signaling pathway via Gq protein coupling. Dopamine D2 receptors, predominant in the striatum, inhibit adenylate cyclase via Gi/o coupling. NMDA receptors function as ligand-gated ion channels that enable calcium influx, essential for synaptic plasticity and learning processes.

Receptor-Specific Analysis of Psychedelic Substances

Serotonin receptors (5-HT)

5-HT2A Agonism

Classic psychedelics show affinity for 5-HT2A receptors:

  • LSD: Partial agonist (EC50 ≈ 3 nM, Emax ≈ 70% of serotonin)
  • Psilocybin/Psilocin: Full agonist (EC50 ≈ 6 nM, Emax ≈ 95%)
  • DMT: Full agonist (EC50 ≈ 12 nM, Emax ≈ 100%)
  • Mescaline: Moderate agonist (EC50 ≈ 150 nM, Emax ≈ 80%)

 

5-HT1A Activation

Various psychedelics also modulate 5-HT1A autoreceptors:

  • Psilocin: Partial agonist (Ki ≈ 8 nM)
  • LSD: Full agonist (Ki ≈ 1 nM)
  • 5-MeO-DMT: Selective agonist (Ki < 0.5 nM)

 

Dopaminergic Receptors

D2 Receptor Affinity

  • LSD: Moderate agonist (Ki ≈ 50 nM)
  • MDMA: Indirect activation via dopamine reuptake inhibition
  • 2C-B: Mild D2 affinity (Ki ≈ 400 nM)

 

NMDA Receptor Antagonism

  • Ketamine: Non-competitive antagonist (IC50 ≈ 0.5 μM)
  • PCP: Strong antagonist (IC50 ≈ 0.1 μM)
  • DXM: Weaker antagonist (IC50 ≈ 10 μM)

 

GABAerg System Interactions

  • Muscimol (Amanita muscaria): Selective GABA-A agonist (EC50 ≈ 1 μM)
  • THIP: Synthetic GABA-A agonist (EC50 ≈ 0.3 μM)

 

Glutamate Modulation

Psychedelics influence glutamatergic transmission via indirect mechanisms:

  • Psilocybin: Increases prefrontal glutamate via 5-HT2A-mediated disinhibition
  • Ketamine: Blocks NMDA receptors → AMPA receptor upregulation